OUTCOMES OF SUBSEQUENT TREATMENT AFTER ATEZOLIZUMAB–BEVACIZUMAB FOR HEPATOCELLULAR CARCINOMA. Vietnam Journal of Community Medicine, v. 67, n. 10, 25 Oct.2026.